GlobalData on MSN

Alvotech faces FDA setback for its Simponi biosimilar AVT05

Alvotech’s inflammation-targeting biosimilar AVT05 has been rejected by the U.S. Food and Drug Administration (FDA) because ...

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Pharmaceutical Technology on MSN

Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz

A lvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare ...
Nasdaq

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Pharmabiz

Alvotech and Advanz Pharma receive UK MHRA marketing approval for Gobivaz

Alvotech and Advanz Pharma receive UK MHRA marketing approval for Gobivaz: Reykjavik, Iceland Saturday, November 8, 2025, 12:00 Hrs [IST] Alvotech, a global biotech company specia ...